Brink's wins UK CMA backing for remedy in planned NCR Atleos acquisition
BCO•UK competition officials accepted in principle a remedy that could clear Brink's planned acquisition of NCR Atleos without a deeper review. Brink's expects the deal to close in early first-quarter 2027 and reiterated its target of $200 million in annual run-rate cost synergies within three years of closing.
1. Proposed UK remedy
The remedy centers on the divestiture of NoteMachine/TestLink UK, with a sale process under way and multiple buyers engaged. The deal is still expected to close in early first-quarter 2027, and Brink's reiterated its target of $200 million in annual run-rate cost synergies within three years of closing.
